Sign up
Pharma Capital

OKYO Pharma sees big opportunities for its dry eye and pain management technology

Kunwar Shailubhai, chief executive of OKYO Pharma Plc (LON:OKYO) discusses with Proactive's Andrew Scott the new direction and investment strategy for the business following its name change earlier this year.

He says they've found two 'exciting' new technologies focused on dry eye and pain management.

'Both are worldwide epidemics ... we think there's a lot of opportunity'', he says.

 

View full OKYO profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.